From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine
Authors
Keywords
-
Journal
Expert Review of Vaccines
Volume 17, Issue 6, Pages 461-477
Publisher
Informa UK Limited
Online
2018-06-09
DOI
10.1080/14760584.2018.1483726
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine
- (2018) Lisa K. McNeil et al. mBio
- Meningococcal Carriage Following a Vaccination Campaign With MenB-4C and MenB-FHbp in Response to a University Serogroup B Meningococcal Disease Outbreak—Oregon, 2015–2016
- (2017) Lucy A McNamara et al. JOURNAL OF INFECTIOUS DISEASES
- Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial
- (2017) Helen S Marshall et al. LANCET INFECTIOUS DISEASES
- A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults
- (2017) Lars Ostergaard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neisseria meningitidis Serogroup B Vaccine, Bivalent rLP2086, Induces Broad Serum Bactericidal Activity Against Diverse Invasive Disease Strains Including Outbreak Strains
- (2017) Shannon L. Harris et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France
- (2017) Muhamed-Kheir Taha et al. VACCINE
- Serogroup B Meningococcus Outbreaks, Prevalence, and the Case for Standard Vaccination
- (2017) James Grogan et al. Current Infectious Disease Reports
- Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine — Advisory Committee on Immunization Practices, 2016
- (2017) Monica E. Patton et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Routinely vaccinating adolescents against meningococcus: targeting transmission & disease
- (2016) Volker Vetter et al. Expert Review of Vaccines
- Immunogenicity of a Meningococcal B Vaccine during a University Outbreak
- (2016) Nicole E. Basta et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents
- (2016) Derek Muse et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine
- (2016) Shelly Senders et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults
- (2016) Lars Ostergaard et al. VACCINE
- Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workers
- (2016) David M. Reiner et al. VACCINE
- Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents
- (2016) Timo Vesikari et al. Journal of the Pediatric Infectious Diseases Society
- Persistence of Meningococcal Antibodies and Response to a Third Dose After a Two-dose Vaccination Series with Investigational MenABCWY Vaccine Formulations in Adolescents
- (2015) Xavier Saez-Llorens et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- First Use of a Serogroup B Meningococcal Vaccine in the US in Response to a University Outbreak
- (2015) L. A. McNamara et al. PEDIATRICS
- MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine
- (2015) Duccio Medini et al. VACCINE
- Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015
- (2015) Jessica R. MacNeil et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2014
- (2015) Sarah Reagan-Steiner et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents
- (2015) Timo Vesikari et al. Journal of the Pediatric Infectious Diseases Society
- Antibody Persistence and Booster Response of a Quadrivalent Meningococcal Conjugate Vaccine in Adolescents
- (2014) Roger Baxter et al. JOURNAL OF PEDIATRICS
- The Discovery and Development of a Novel Vaccine to Protect againstNeisseria meningitidisSerogroup B Disease
- (2014) Gary W Zlotnick et al. Human Vaccines & Immunotherapeutics
- Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study
- (2013) Charissa Borja-Tabora et al. BMC INFECTIOUS DISEASES
- A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
- (2013) Miguel O’Ryan et al. DRUGS
- Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2–10-year-old children: results of an open, randomised, controlled study
- (2013) Markus Knuf et al. EUROPEAN JOURNAL OF PEDIATRICS
- Missed Opportunities for Adolescent Vaccination, 2006–2011
- (2013) Charlene A. Wong et al. JOURNAL OF ADOLESCENT HEALTH
- Role of Factor H Binding Protein in Neisseria meningitidis Virulence and Its Potential as a Vaccine Candidate To Broadly Protect against Meningococcal Disease
- (2013) L. K. McNeil et al. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS
- Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage
- (2013) Giacomo Frosi et al. VACCINE
- A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults
- (2013) Helen S. Marshall et al. VACCINE
- Persistence of antibodies in adolescents 18−24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine
- (2013) Maria Elena Santolaya et al. Human Vaccines & Immunotherapeutics
- Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): Lessons from past programs and implications for the future
- (2013) Johan Holst et al. Human Vaccines & Immunotherapeutics
- Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial
- (2012) Peter C Richmond et al. LANCET INFECTIOUS DISEASES
- A Randomized, Controlled, Phase 1/2 Trial of a Neisseria meningitidis Serogroup B Bivalent rLP2086 Vaccine in Healthy Children and Adolescents
- (2012) Michael D. Nissen et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation phase 1 trial
- (2012) P.C. Richmond et al. VACCINE
- A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults
- (2012) Eric Sheldon et al. Human Vaccines & Immunotherapeutics
- BIGSdb: Scalable analysis of bacterial genome variation at the population level
- (2011) Keith A Jolley et al. BMC BIOINFORMATICS
- Changing epidemiology of meningococcal disease in Europe from the mid-20th to the early 21st Century
- (2011) Paula Kriz et al. Expert Review of Vaccines
- Preclinical evidence for the potential of a bivalent fHBP vaccine to preventNeisseria meningitidisSerogroup C Disease
- (2011) Shannon L. Harris et al. Human vaccines & immunotherapeutics
- Meningococcal carriage by age: a systematic review and meta-analysis
- (2010) Hannah Christensen et al. LANCET INFECTIOUS DISEASES
- Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease
- (2010) Han-Qing Jiang et al. VACCINE
- Changes inNeisseria meningitidisDisease Epidemiology in the United States, 1998–2007: Implications for Prevention of Meningococcal Disease
- (2009) Amanda C. Cohn et al. CLINICAL INFECTIOUS DISEASES
- Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup BNeisseria meningitidis
- (2009) Ellen Murphy et al. JOURNAL OF INFECTIOUS DISEASES
- A Randomized Trial to Determine the Tolerability and Immunogenicity of a Quadrivalent Meningococcal Glycoconjugate Vaccine in Healthy Adolescents
- (2009) Lisa A. Jackson et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease
- (2009) Carl E. Frasch et al. VACCINE
- Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide
- (2009) Lisa K. McNeil et al. VACCINE
- Delivering Adolescent Vaccinations in the Medical Home: A New Era?
- (2008) Peter G. Szilagyi et al. PEDIATRICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started